SCHEMBL419847

SCHEMBL419847

C#Cc1ccc(C23CC4CC(CC(C4)C2)C3)cc1

nearest known ligand 0.57

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.57
ALDH1A1 P00352 3/20 0.57
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
EPHX2 P34913 6/20 0.47
GAA P10253 2/20 0.47
POLB P06746 1/20 0.47
GFER P55789 1/20 0.47
PGR P06401 6/20 0.46
RAB9A P51151 1/20 0.45
NPC1 O15118 1/20 0.45
MAPT P10636 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6368529 0.84 PGR (0.46) LMNAALDH1A1MEN1KMT2AL3MBTL1
SCHEMBL7103212 0.84 LMNA (0.45) LMNAALDH1A1MEN1KMT2AL3MBTL1
SCHEMBL2763437 0.82 LMNA (0.77) LMNAALDH1A1MEN1KMT2AL3MBTL1
SCHEMBL19089867 0.81 PGR (0.40) LMNAALDH1A1MEN1KMT2AL3MBTL1
SCHEMBL4752577 0.80 PGR (0.68) LMNAALDH1A1MEN1KMT2AL3MBTL1
SCHEMBL6698243 0.80 LMNA (0.47) LMNAALDH1A1MEN1KMT2AL3MBTL1
SCHEMBL10012162 0.80 LMNA (0.57) LMNAALDH1A1MEN1KMT2AL3MBTL1
SCHEMBL10012784 0.80 LMNA (0.57) LMNAALDH1A1MEN1KMT2AL3MBTL1
SCHEMBL6684731 0.77 LMNA (0.53) LMNAALDH1A1MEN1KMT2AL3MBTL1
SCHEMBL2763378 0.77 PGR (0.55) LMNAALDH1A1MEN1KMT2APGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114920907-B Aminated porous aromatic skeleton compound and preparation method and application thereof 福建农林大学 2023-06-20 CN claimed
CN-114920907-A Aminated porous aromatic skeleton compound and preparation method and application thereof 福建农林大学 2022-08-19 CN claimed
CN-114618450-B Conjugated microporous polymer composite material, preparation method thereof and adsorbent 北京石墨烯技术研究院有限公司 2022-08-02 CN claimed
CN-114618450-A Conjugated microporous polymer composite material, preparation method thereof and adsorbent 北京石墨烯技术研究院有限公司 2022-06-14 CN claimed
CN-114920907-B Aminated porous aromatic skeleton compound and preparation method and application thereof 福建农林大学 2023-06-20 CN disclosed
CN-114920907-A Aminated porous aromatic skeleton compound and preparation method and application thereof 福建农林大学 2022-08-19 CN disclosed
CN-114618450-B Conjugated microporous polymer composite material, preparation method thereof and adsorbent 北京石墨烯技术研究院有限公司 2022-08-02 CN disclosed
CN-114618450-A Conjugated microporous polymer composite material, preparation method thereof and adsorbent 北京石墨烯技术研究院有限公司 2022-06-14 CN disclosed
CN-112961110-B Olefin functionalized IPr HCl monomer and preparation method and application thereof 浙江工业大学 2022-05-24 CN disclosed
CN-114168587-A System and method for generating smell data and database thereof 苏星 2022-03-11 CN disclosed
CN-112961110-A Olefin functionalized IPr HCl monomer and preparation method and application thereof 浙江工业大学 2021-06-15 CN disclosed
EP-2607348-B1 Plasminogen Activator Inhibitor-1 Inhibitor RENASCIENCE INC (JP) 2021-03-17 EP disclosed
US-20140296256-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR RENASCIENCE CO LTD (JP) 2014-10-02 US disclosed
US-8785473-B2 Plasminogen activator inhibitor-1 inhibitor RENASCIENCE CO., LTD. (JP) 2014-07-22 US disclosed
EP-2607348-A2 Plasminogen Activator Inhibitor-1 Inhibitor Renascience CO., LTD. (JP) 2013-06-26 EP disclosed
EP-2415755-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR Renascience CO., LTD. (JP) 2012-02-08 EP disclosed
US-20120022080-A1 Plasminogen Activator Inhibitor-1 Inhibitor RENASCIENCE CO., LTD. (JP) 2012-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140296256-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR SERPINE1, SERPINC1, SERPINB1 LMNA 482/4885ALDH1A1 1450/4885MEN1 844/4885
US-20120022080-A1 Plasminogen Activator Inhibitor-1 Inhibitor SERPINE1, SERPINC1, SERPINB1 LMNA 482/4885ALDH1A1 1450/4885MEN1 844/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.